PDF factsheet
      Z

All mechanism in melanoma for adjuvant setting, clinical trials results

ID IFN alpha-2b (I M) versus observation
EORTC18952 (Eggermont), 2005

versus
patients who had had a thick primary tumour (thickness4 mm) resected (stage IIb) or regional lymph node metastases dissected (stage III)
Follow-up duration: 4.65 years
Nordic IFN Trial, 2011
intermediate-dose interferon alfa-2b duration 1
versus
duration 2
patients with stage IIB-IIC or III resected cutaneous melanoma.
Follow-up duration: 72·4 months
ipilimumab versus placebo
EORTC 18071 (Eggermont), 2015
NCT00636168
ipilimumab at a dose of 10 mg per kilogram every 3 weeks for four doses, then every 3 months for up to 3 years or until disease recurrence or an unacceptable level of toxic effects occurred
versus
placebo
high risk patients who had undergone complete resection of stage III melanomadouble-blind
Follow-up duration: 5.3 years
nivolumab versus ipilimumab
CheckMate 238, 2017
NCT02388906
nivolumab at a dose of 3 mg per kilogram of body weight every 2 weeks
versus
ipilimumab at a dose of 10 mg per kilogram every 3 weeks for four doses and then every 12 weeks
patients with Complete Resection of Stage IIIb/c or Stage IV Melanomadouble-blind
Follow-up duration: 18 months (median)
US
PEG IFN alpha-2b (I M) versus observation
EORTC18991 (Eggermont), 2008
pegylated interferon alfa-2b 6 mug/kg per week for 8 weeks (induction) then 3 mug/kg per week (maintenance) for an intended duration of 5 years
versus
patients with resected stage III melanoma
Follow-up duration: 3.8 years
pembrolizumab versus placebo
KEYNOTE-054, 2018
NCT02362594
Pembrolizumab (Participants receive pembrolizumab 200 mg intravenously (IV) on Day 1 of each 21-day cycle for up to 1 year)
versus
placebo
patients with complete Resection of High-Risk Stage III Melanomadouble-blind
Follow-up duration: 15 months (median)
rIFN alpha-2b versus observation
EORTC18871/DKG 80-1 (Kleeberg), 2004
rIFN-alpha2b
versus
observation
High-risk stage II patients (thickness >3 mm) and stage III patients (positivelymph nodes) without distant metastasis
Follow-up duration: 8.2 years (median)
trametinib and dabrafenib versus placebo
COMBI-AD, 2017
NCT01682083
dabrafenib (150 mg twice daily) and trametinib (2 mg once daily) orally for 12 months
versus
placebo
Patients with completely resected, histologically confirmed, BRAF V600E/K mutation-positive, high-risk [Stage IIIa (lymph node metastasis >1 mm), IIIb or IIIc] cutaneous melanomadouble-blind
trametinib and dabrafenib versus SOC
COMBI neo, 2018
NCT02231775

versus
vemurafenib versus placebo
BRIM 8, 2018
NCT01667419
e twice-daily adjuvant oral vemurafenib 960 mg tablets for52 weeks (13×28-day cycles)
versus
placebo
patients with resected,BRAFV600 mutation-positive melanoma: IC–IIIA–IIIB (cohort 1) or stage IIIC (cohort 2)

  Options


in first

in second

  Filter